基因克隆服务市场－全球产业规模、份额、趋势、机会及预测（按服务类型、基因类型、应用、最终用户、地区和竞争格局划分，2021-2031年）

全球基因克隆服务市场预计将从 2025 年的 35.9 亿美元成长到 2031 年的 85.4 亿美元，复合年增长率达 15.54%。

这些服务包括用于组装重组DNA分子并在宿主生物体中复製以创建相同基因拷贝的专业实验室技术，涵盖诱变、质体设计、基因合成等关键过程。该市场的主要成长要素是生物技术产业的快速发展，尤其是在生物製药开发领域；对个人化医疗的需求不断增长；以及为应对慢性病和遗传疾病日益增多而加快研究工作流程的必要性。

然而，由于先进克隆技术营运成本高且技术复杂，市场面临许多挑战，这为小规模研究机构进入该领域设置了准入门槛。儘管存在这些挑战，但行业趋势表明，对这些服务的需求仍然至关重要。根据美国基因与细胞治疗学会 (ASGCT) 预测，到 2025 年，全球将进行超过 3,200 项基因、细胞和 RNA 疗法的临床试验，凸显了克隆服务在维持这庞大的治疗开发平臺中所发挥的关键作用。

市场驱动因素

基因和细胞疗法需求的激增是全球基因克隆服务市场的主要驱动力。随着製药研发管线向生物製药领域集中，对精准克隆的需求日益增长，以生产用于肿瘤和罕见遗传疾病治疗的病毒载体、重组质体和修饰DNA序列。监管政策的发展进一步推动了这项需求。根据再生医学联盟2024年1月发布的《产业趋势》报告，2023年美国和欧盟将核准创纪录的五种罕见疾病基因疗法。这表明该市场日趋成熟，并将高度依赖可扩展的克隆工作流程。

此外，政府和私人对生命科学领域的投入增加，正在加速克隆操作外包模式的转变。这种财政支持使得学术机构和生物技术公司能够利用专业服务提供者，而无需投资建设资本密集的内部设施。研发投入的大幅成长也支撑了这个趋势。根据美国药品研究与製造商协会（PhRMA）于2024年8月发布的《2024年会员调查报告》，预计会员公司在2023年的研发投入将达到1,035亿美元。这种强劲的资金环境直接惠及服务供应商，Twist Bioscience于2024年11月发布的2024年财务报告显示，其总收入为3.13亿美元，反映出该公司对合成生物学和克隆服务的依赖程度日益加深。

市场挑战

先进基因克隆技术的复杂性和高昂的营运成本严重限制了全球基因克隆服务市场的成长。这些复杂的技术需要昂贵的设备、专用试剂和高技能人员，给新兴生物技术公司和小规模研究机构带来了巨大的经济负担。因此，这些代理商往往难以获得足够的预算来外包关键服务，从而限制了其潜在基本客群，并减缓了精准克隆技术的广泛应用。

由于近期该产业核心客户群可获得的投资资本减少，这项财务负担进一步加剧。根据生技创新组织（BIO）预测，生技Start-Ups公司的资金筹措预计将在2025年大幅下降，从第一季的26亿美元降至第二季的9亿美元。融资金额的显着下降迫使早期公司缩减研发活动，从而降低了对外部基因克隆服务的需求，并阻碍了市场的快速扩张潜力。

市场趋势

人工智慧（AI）辅助序列优化技术的整合正在透过改进复杂基因构建体的预测设计，变革基因克隆领域。利用先进的演算法进行大规模数据分析，供应商能够在合成前优化密码子使用、预测二级结构并识别不稳定区域，从而降低失败率并加快从设计到上市的时间。这项技术的影响深远：根据皮斯托亚联盟于2025年9月发布的《未来实验室2025调查报告》，77%的生命科学实验室计画在未来两年内实施人工智慧技术，这标誌着基因工程领域正向计算精度方向发生重大转变。

同时，自动化高通量克隆平台的引入，透过实现大规模文库的快速处理，正在彻底改变克隆规模。透过以机器人液体处理系统取代人工移液，服务供应商可以同时进行数千个克隆反应，显着缩短突变体文库建构和大规模质体製备的周转时间。这些营运效率的提升正在推动商业性成长。金斯瑞生技股份有限公司于2025年3月发布的「2024财年财务表现」预测，持续经营业务的营收将达到5.945亿美元，这印证了该公司在支持其向工业规模克隆扩张方面取得的财务成功。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球基因克隆服务市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依服务类型（基因合成服务、分子生物学服务、客製化克隆服务、其他）
  • 依基因类型（单链基因、复杂基因等）
  • 依应用领域（基因合成、基因表现、基因治疗、疫苗研究等）
  • 依最终用户（製药/生技公司、临床试验机构等）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美基因克隆服务市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲基因克隆服务市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区基因克隆服务市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲基因克隆服务市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲基因克隆服务市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球基因克隆服务市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific, Inc
• Eurofins Scientific SE
• GenScript Biotech Corp
• Merck KGaA
• Takara Bio Inc
• Charles River Laboratories International, Inc
• Sartorius AG
• Cellecta, Inc
• Creative Biogene, Inc
• Biocompare, Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Gene Cloning Services Market is projected to expand from USD 3.59 Billion in 2025 to USD 8.54 Billion by 2031, registering a CAGR of 15.54%. These services involve specialized laboratory techniques designed to assemble recombinant DNA molecules and replicate them within host organisms to create identical genetic copies, encompassing essential processes such as mutagenesis, plasmid design, and gene synthesis. The market is primarily driven by the booming biotechnology sector, particularly in biologics development, and the increasing demand for personalized medicine, alongside the need to accelerate research workflows to address the rising prevalence of chronic and genetic diseases.

However, the market faces obstacles due to the high operational costs and technical complexities of advanced cloning procedures, which create entry barriers for smaller research entities. Despite these challenges, the necessity for these services remains critical, as reflected in industry activity. According to the American Society of Gene & Cell Therapy, over 3,200 gene, cell, and RNA therapy trials were active globally in 2025, highlighting the indispensable role of cloning services in sustaining this extensive pipeline of therapeutic developments.

Market Driver

The surging demand for gene and cell therapies acts as a major catalyst for the Global Gene Cloning Services Market. As pharmaceutical pipelines increasingly focus on biologics, the need for precision cloning to produce viral vectors, recombinant plasmids, and modified DNA sequences for treating oncology and rare genetic disorders has intensified. This demand is further supported by regulatory achievements; according to the Alliance for Regenerative Medicine's January 2024 "State of the Industry" report, a record five gene therapies for rare diseases received approval in the United States and European Union in 2023, indicating a maturing market that depends heavily on scalable cloning workflows.

Additionally, rising government funding and private investment in life sciences are accelerating the shift toward outsourced cloning models. This financial support enables academic centers and biotech firms to utilize specialized providers rather than investing in capital-intensive in-house facilities. This trend is underscored by substantial R&D spending; PhRMA's "2024 Membership Survey" from August 2024 notes that member companies invested USD 103.5 billion in research and development in 2023. This robust funding environment directly benefits service providers, as evidenced by Twist Bioscience's "Fiscal 2024 Financial Results" in November 2024, which reported USD 313 million in total revenue, reflecting the growing reliance on synthetic biology and cloning services.

Market Challenge

The substantial technical complexity and high operational costs associated with advanced gene cloning procedures present a significant barrier to the growth of the Global Gene Cloning Services Market. These intricate techniques require expensive instrumentation, specialized reagents, and highly skilled personnel, establishing steep financial hurdles for emerging biotechnology firms and smaller research institutions. Consequently, these entities often struggle to allocate sufficient budgets for outsourcing critical services, which limits the potential customer base and slows the broader adoption of precision cloning technologies.

This financial strain is further highlighted by recent declines in investment capital available to the sector's core clientele. According to the Biotechnology Innovation Organization, biotech startup funding dropped sharply in 2025, falling from 2.6 billion dollars in the first quarter to 900 million dollars in the second quarter. This significant reduction in capital forces early-stage companies to scale back their research and development activities, thereby diminishing the demand for external gene cloning services and impeding the market's potential for rapid expansion.

Market Trends

The integration of Artificial Intelligence for Sequence Optimization is transforming the gene cloning landscape by improving the predictive design of complex genetic constructs. Advanced algorithms are increasingly utilized to analyze large datasets, allowing providers to optimize codon usage, predict secondary structures, and identify instability regions prior to synthesis, thus reducing failure rates and accelerating the design-to-product timeline. The impact of this technology is significant; according to the Pistoia Alliance's "2025 Lab of the Future Survey" released in September 2025, 77% of life sciences laboratories plan to adopt AI technologies within the next two years, signaling a major shift toward computational precision in genetic engineering.

Simultaneously, the deployment of Automated High-Throughput Cloning Platforms is revolutionizing scalability by enabling the rapid processing of massive libraries. By replacing manual pipetting with robotic liquid handling systems, service providers can execute thousands of cloning reactions concurrently, drastically reducing turnaround times for mutant library construction and large-scale plasmid preparation. This operational efficiency is driving commercial growth, as illustrated by GenScript Biotech Corporation's "FY 2024 Results" in March 2025, which reported continuing operations revenue of USD 594.5 million, underscoring the financial success supporting their industrial-scale cloning expansion.

Key Market Players

• Thermo Fisher Scientific, Inc
• Eurofins Scientific SE
• GenScript Biotech Corp
• Merck KGaA
• Takara Bio Inc
• Charles River Laboratories International, Inc
• Sartorius AG
• Cellecta, Inc
• Creative Biogene, Inc
• Biocompare, Inc

Report Scope

In this report, the Global Gene Cloning Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Cloning Services Market, By Service Type

• Gene Synthesis Service
• Molecular Biology Service
• Custom Cloning Service
• Others

Gene Cloning Services Market, By Gene Type

• Stranded Gene
• Complex Gene
• Others

Gene Cloning Services Market, By Application

• Gene Synthesis
• Gene Expression
• Gene Therapy
• Vaccine Research
• Others

Gene Cloning Services Market, By End User

• Pharmaceutical & Biotechnology Companies
• Clinical Laboratories
• Others

Gene Cloning Services Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Cloning Services Market.

Available Customizations:

Global Gene Cloning Services Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gene Cloning Services Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Service Type (Gene Synthesis Service, Molecular Biology Service, Custom Cloning Service, Others)
  • 5.2.2. By Gene Type (Stranded Gene, Complex Gene, Others)
  • 5.2.3. By Application (Gene Synthesis, Gene Expression, Gene Therapy, Vaccine Research, Others)
  • 5.2.4. By End User (Pharmaceutical & Biotechnology Companies, Clinical Laboratories, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Gene Cloning Services Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Service Type
  • 6.2.2. By Gene Type
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Gene Cloning Services Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Service Type
      • 6.3.1.2.2. By Gene Type
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Gene Cloning Services Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Service Type
      • 6.3.2.2.2. By Gene Type
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Gene Cloning Services Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Service Type
      • 6.3.3.2.2. By Gene Type
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Gene Cloning Services Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Service Type
  • 7.2.2. By Gene Type
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Gene Cloning Services Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Service Type
      • 7.3.1.2.2. By Gene Type
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. France Gene Cloning Services Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Service Type
      • 7.3.2.2.2. By Gene Type
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Gene Cloning Services Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Service Type
      • 7.3.3.2.2. By Gene Type
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Gene Cloning Services Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Service Type
      • 7.3.4.2.2. By Gene Type
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Gene Cloning Services Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Service Type
      • 7.3.5.2.2. By Gene Type
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific Gene Cloning Services Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Service Type
  • 8.2.2. By Gene Type
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Gene Cloning Services Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Service Type
      • 8.3.1.2.2. By Gene Type
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Gene Cloning Services Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Service Type
      • 8.3.2.2.2. By Gene Type
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Gene Cloning Services Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Service Type
      • 8.3.3.2.2. By Gene Type
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Gene Cloning Services Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Service Type
      • 8.3.4.2.2. By Gene Type
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Gene Cloning Services Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Service Type
      • 8.3.5.2.2. By Gene Type
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Middle East & Africa Gene Cloning Services Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Service Type
  • 9.2.2. By Gene Type
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Gene Cloning Services Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Service Type
      • 9.3.1.2.2. By Gene Type
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Gene Cloning Services Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Service Type
      • 9.3.2.2.2. By Gene Type
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Gene Cloning Services Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Service Type
      • 9.3.3.2.2. By Gene Type
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. South America Gene Cloning Services Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Service Type
  • 10.2.2. By Gene Type
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Gene Cloning Services Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Service Type
      • 10.3.1.2.2. By Gene Type
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Gene Cloning Services Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Service Type
      • 10.3.2.2.2. By Gene Type
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Gene Cloning Services Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Service Type
      • 10.3.3.2.2. By Gene Type
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Gene Cloning Services Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific, Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Eurofins Scientific SE
• 15.3. GenScript Biotech Corp
• 15.4. Merck KGaA
• 15.5. Takara Bio Inc
• 15.6. Charles River Laboratories International, Inc
• 15.7. Sartorius AG
• 15.8. Cellecta, Inc
• 15.9. Creative Biogene, Inc
• 15.10. Biocompare, Inc

16. Strategic Recommendations

17. About Us & Disclaimer